Inhalation Sciences

Ulf Wedenberg has over 25 years of experience from leading roles in sales, marketing and business development in the pharmaceutical and medical device sector. He has previously held key positions in companies such as Mölnlycke Healthcare, Nycomed och SHL Healthcare, where he built and led international commercial organizations with a focus on profitable growth and long-term market establishment.

"Inhalation Sciences has world-leading, patented technologies and offers unique CRO services in inhaled and nasally administered drugs. The company is in a very dynamic phase with a strong focus on growth. I am proud to become part of the team and look forward to contributing to the company's development together with all the dedicated colleagues", says Ulf Wedenberg.

"We are very pleased to welcome Ulf to ISAB. This appointment is in line with our strategy to drive continued growth and strengthen our market position. With Ulf's experience and commercial expertise, we are gaining an important reinforcement in our commercial efforts", says Manoush Masarrat, CEO of Inhalation Sciences.

Ulf Wedenberg will assume his new role on June 2, 2025.

For more information, please contact:

Manoush Masarrat, CEO

E-mail: manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.